Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB
ABP-2019
Phase 2 small_molecule active
Quick answer
Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB for locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active